Drugs / Calcium supplement
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00000415 | Apr 1998 → Feb 2003 | — | South Dakota State University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06160479 | May 2022 → Sep 2023 | calcium metabolic disease | Siriraj Hospital | Unknown | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1/2 | NCT01624064 Comparator | Aug → Oct 2012 | chronic kidney disease | Ministry of Health, Sri Lanka | Unknown | No outcome recorded |
| Phase 3 | NCT00729183 Background | Oct 2008 → Mar 2010 | osteoporosis | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00670501 Background | Aug 1996 → Apr 1999 | postmenopausal osteoporosis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01753856 Background | Jan 2013 → Jun 2014 | osteoporosis | Eli Lilly and Company | Completed | Met primary |
| — | NCT07364279 Background | Nov 2024 → Nov 2025 | osteoporosis | Cairo University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcium supplement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000415 ↗ |
| Route | Oral | “Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement” NCT00670501 ↗ |